For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

24th Aug 16

Stopping scars before they form

Pharmaxis is working with senior Western Australian researchers on a potential new scar treatment for burns, keloids and Dupuytren contracture. Early stage research has been presented at the prestigious American Chemical Society meeting in Philadelphia.

Read full media release - pdf
15th Jul 16

Pharmaxis Completes Recruitment of Pivotol Bronchitol Cystic Fibrosis Clinical Trial for US Market

Pharmaceutical research company Pharmaxis today announced it has completed recruitment of its international clinical trial evaluating Bronchitol® (mannitol) in adults with cystic fibrosis. The results of the trial (CF303) are expected to be reported in the second quarter of 2017.

The Phase 3 trial is being conducted in accordance with the requirements of the US Food and Drug Administration (FDA) to gain approval for Bronchitol to treat cystic fibrosis (CF) in the United States in adult patients. Subject to a positive trial outcome, the Company will submit a response to the FDA and a decision on approval can be expected in 2018.

Read full media release - pdf
4th Jul 16

Company Overview (June 2016)

Valuable Development Pipeline with the Funds to Exploit

Summary of Pharmaxis business, risks and catalysts at June 2016

Read full media release - pdf